Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dusquetide - Soligenix

Drug Profile

Dusquetide - Soligenix

Alternative Names: Dusquetide; IDR-1; Innate defense regulator-1; SGX-94; SGX-942; SGX-943

Latest Information Update: 17 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of British Columbia
  • Developer Soligenix; The Childrens Hospital of Philadelphia
  • Class Anti-inflammatories; Antibacterials; Peptides; Proteins
  • Mechanism of Action Immunomodulators; SQSTM1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders; Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Stomatitis
  • Preclinical Bacterial infections; Lymphoproliferative disorders; Melioidosis
  • No development reported Acute radiation syndrome

Most Recent Events

  • 17 Sep 2020 9302956: No updates
  • 24 Jun 2020 Soligenix completes enrolment in the phase III DOM–INNATE trial for Stomatitis (Chemotherapy-induced) in the US, Belgium, Spain, UK, Hungary, Poland and France
  • 03 Feb 2020 Soligenix receives patent allowance for dusquetide in Oral mucositis in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top